The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

H.C. Wainwright upgraded Sarepta (SRPT) to Neutral from Sell with an unchanged price target of $75. The firm cites the stock’s current ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by stock analysts at Royal Bank of Canada from an ...